Barbara P. Wallner
34Patents
13h-index
18Co-inventors
78Inventor score
Filing activity: Jan 10, 1985 → Nov 6, 2013
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6258597A | Stimulation of hematopoietic cells in vitro | Chemistry; Metallurgy | 80 | Expired |
| US6300314A | Hematopoietic stimulation | Human Necessities | 78 | Expired |
| US4956281A | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 | Human Necessities | 71 | Expired |
| US6162432A | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction | Chemistry; Metallurgy | 66 | Expired |
| US6355614B1 | Cyclic boroproline compounds | Chemistry; Metallurgy | 52 | Expired |
| US6703238B2 | Methods for expanding antigen-specific T cells | Chemistry; Metallurgy | 41 | Expired |
| US5547853A | CD2-binding domain of lymphocyte function associated antigen 3 | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6890904B1 | Anti-tumor agents | Human Necessities | 34 | Expired |
| US5223394A | Recombinant DNA molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence | Chemistry; Metallurgy | 33 | Expired |
| US4879224A | DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides | Human Necessities | 24 | Expired |
| US6949514B2 | Anti-tumor agents | Human Necessities | 16 | Expired |
| US6770628B2 | Hematopoietic stimulation | Human Necessities | 16 | Expired |
| US6979697B1 | Regulation of substrate activity | Human Necessities | 13 | Expired |
| US7323171B2 | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction | Physics | 13 | Expired |
| US5081019A | DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides | Human Necessities | 12 | Expired |
| US4874743A | DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides | Human Necessities | 12 | Expired |
| US5484711A | DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI | Human Necessities | 11 | Expired |
| US5914111A | CD2-binding domain of lymphocyte function associated antigen-3 | Emerging Cross-Sectional Technologies | 10 | Expired |
| US4950646A | DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides | Human Necessities | 9 | Expired |
| US5185441A | DNA sequences, recombinant DNA molecules and processes for producing PI-linked lymphocyte function associated antigen-3 | Human Necessities | 9 | Expired |
| US5728677A | Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3 | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7282484B2 | Anti-tumor agents | Human Necessities | 8 | Active |
| US5298489A | DNA sequences recombinant DNA molecules and processes for producing lipocortins III, IV, V and VI | Human Necessities | 7 | Expired |
| US5928643A | Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation | Chemistry; Metallurgy | 7 | Expired |
| US6764681B2 | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction | Physics | 6 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.